EDITION OF FRI 13 NOV 2026
160 · BUSINESS

FDA orders vision-loss risk warnings for GLP-1 drugs

publishers 50articles 53first reported 9 Nov, 16:45 UTCdeveloping since 9 Nov · 8 editions

The U.S. Food and Drug Administration is requiring makers of GLP-1 medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, to add warnings about a potential increased risk of a rare eye condition that can cause permanent vision loss.

The condition, non-arteritic anterior ischemic optic neuropathy, or NAION, occurs when blood flow to the optic nerve decreases. It can cause sudden, painless loss of vision, usually in one eye. The FDA said patients who have previously experienced NAION face an increased risk.

The agency said its decision followed a review of clinical trials, observational studies and other evidence, including research published in 2024 that prompted further investigation. An FDA analysis of 126 randomized controlled trials found 6.4 NAION cases per 100,000 person-years among patients treated with GLP-1 drugs, compared with 3.8 cases among those receiving a placebo or a non-GLP-1 glucose-lowering medicine.

The findings indicate a possible association but do not establish that GLP-1 medicines cause NAION. Novo Nordisk, which makes Ozempic and Wegovy, said available research does not establish a causal link.

The FDA directed manufacturers to add the potential risk to the Warnings and Precautions section of product labels. It also said health-care providers should consider advising patients to stop GLP-1 treatment if signs of NAION develop, unless the benefits clearly outweigh the risk.

HOW THIS STORY WAS MADE

Written from 8 articles, 3 with the publisher's own text; 8 independent newsrooms once syndicated copies count as one; this version written 72 h after the record first saw the story; the editor kept it as written.

Publishers
50
Source articles
53
Given to the writer
8, 3 with the article's own text
Independent newsrooms
8
This version written
72 h after the record first saw the story
Second model (editor)
kept as written
Publication gate
passed
Human review
none

WHAT THE EDITOR DID

The second model checked the writer's draft against the same sources and published it as written.

Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →

NAMED IN THE COVERAGE

OUTLETS CARRYING THE STORY, RUN BY RUN

0 25 51 10 Nov 11 Nov 12 Nov 13 Nov 14 Nov 15 Nov 16 Nov 10 Nov 00:19 UTC · US FDA orders new eye risk warnings for Ozempic, Zepbound 10 Nov 06:14 UTC · US FDA orders new eye risk warnings for Ozempic, Zepbound 10 Nov 18:17 UTC · US FDA orders new eye risk warnings for Ozempic, Zepbound 11 Nov 00:15 UTC · US FDA orders new eye risk warnings for Ozempic, Zepbound 11 Nov 12:16 UTC · FDA orders vision-loss risk warning for GLP-1 drugs 12 Nov 18:29 UTC · FDA orders vision-loss risk warnings for GLP-1 drugs

WHAT HELD, WHAT CAME LATER

From the first reports to the latest

  • Novo Nordisk · 3 outlets
  • Eli Lilly · 2 outlets

Entered the story later

  • 126 clinical trials · from 11 Nov 08:45, 2 outlets
  • 100,000 person-years among · from 11 Nov 08:45, 2 outlets
  • 100,000 people followed · from 11 Nov 08:45, 2 outlets

Figures reported with different numbers

  • people followed: 100,000 (2 from 11 Nov 08:45) → 50,000 (1 from 11 Nov 08:45)

Matched by pattern, not read: a different number can be a correction, a rising count, or two different counts.

HOW THIS STORY DEVELOPED: EVERY HEADLINE, EVERY OUTLET →